Clinical trials
Leukemia, Myeloid, Acute clinical trials
Below are recruiting leukemia, myeloid, acute clinical trials, each written for real people, not researchers. We’re tracking 595 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06466395RecruitingPhase 1
Hyper-CVAD plus venetoclax for relapsed pediatric leukemia
This trial tests a combination of chemotherapy drugs (hyper-CVAD) plus a targeted pill called venetoclax for children and young adults with a type of leukemia that has returned or not responded to treatment. The goal is to see if this combo can help control the leukemia.
Houston, TexasAges 2–21 - NCT05305859RecruitingPhase 2
Venetoclax, chidamide, and azacitidine for hard-to-treat AML
This Phase 2 trial tests whether adding three medicines—venetoclax, chidamide, and azacitidine—can help adults whose AML has come back or did not respond to treatment. It may help shrink or control the leukemia and improve outcomes for people who fit the study’s health and lab requirements.
Xiamen, FujianAges 18 years+ - NCT06459024Recruiting
Master study for relapsed or hard-to-treat acute myeloid leukemia
This trial is for people with acute myeloid leukemia (AML) that has come back (relapsed) or is not responding to treatment (refractory). It tests different new treatments to find which ones work best.
AachenAges 6 years+ - NCT06448013RecruitingPhase 1
Ziftomenib with chemo for pediatric AML
This trial tests a new drug, ziftomenib, combined with two standard chemotherapies (venetoclax and gemtuzumab) for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells.
Houston, TexasAges 3–21 - NCT06452732Recruiting
Leukemia stem cell test for AML relapse in children
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT06440135RecruitingPhase 1
Ziftomenib maintenance after stem cell transplant for AML
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
Boston, MassachusettsAges 18 years+ - NCT06429449RecruitingPhase 1
Mitoxantrone for venetoclax-resistant AML
This trial tests a re-purposed drug, mitoxantrone, for people whose AML has not responded to or has come back after standard frontline treatment. The goal is to see if this older drug can help overcome resistance to venetoclax.
Aurora, ColoradoAges 18–80 - NCT06399640RecruitingPhase 1
Eltanexor and venetoclax for blood cancers
This trial tests a combination of two oral drugs, eltanexor and venetoclax, for people with certain types of blood cancer that have come back or not responded to previous treatment. The goal is to see if this combination can help control the disease.
Memphis, TennesseeAges 18 years+ - NCT06401603RecruitingPhase 1
Study of three drugs for advanced CML and Ph+ AML
This trial tests a combination of three drugs (decitabine, lisaftoclax, and olverembatinib) for people with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia who have not responded to or could not tolerate previous treatments.
Houston, TexasAges 18 years+ - NCT01311258Recruiting
Tracking leftover cancer cells in AML or high-risk MDS
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
Rochester, New YorkAges 18 years+ - NCT06389292RecruitingPhase 3
Study of Lisaftoclax plus azacitidine for new AML
This study tests a new pill (APG-2575, also called Lisaftoclax) combined with a standard injection (azacitidine) for adults with newly diagnosed AML who cannot take strong chemotherapy. The goal is to see if this combination works better than treatment alone.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT06372717RecruitingPhase 1
Testing APL-4098 alone or combined for AML or MDS
This trial tests a new drug called APL-4098, given alone or with another medicine, for people with certain blood cancers (AML or MDS) that have come back or not responded to treatment. The goal is to see if it is safe and works well.
Clayton, VictoriaAges 18 years+ - NCT06376162RecruitingPhase 1
Ziftomenib with chemotherapy for children with relapsed leukemia
This trial tests whether adding a new drug called ziftomenib to standard chemotherapy can help children whose leukemia has come back or not responded to treatment. It is for children with certain genetic changes in their leukemia cells.
Los Angeles, CaliforniaAges birth–21 years - NCT06370000RecruitingPhase 4
Oral azacitidine for AML patients with health disparities
This trial tests an oral medication (azacitidine) for people with AML who are in remission and planning a stem cell transplant. It focuses on patients who face health disparities, such as financial or access barriers, to help make transplant more successful for everyone.
Richmond, VirginiaAges 18 years+ - NCT06357182RecruitingPhase 1
New drug combo for AML patients who can't have strong chemo
This trial tests a new drug combination (iadademstat plus azacitidine and venetoclax) for people with newly diagnosed AML who cannot have or do not want standard intensive chemotherapy. The goal is to see if adding iadademstat makes the treatment work better.
Portland, OregonAges 18 years+ - NCT06345027RecruitingPhase 1
CAR T cell therapy targeting CD70 for leukemia
This trial tests a new treatment made from your own immune cells, called CAR T cells, that are designed to find and attack leukemia cells with a specific marker called CD70. It may be an option if your leukemia has come back or not responded to standard treatments and you might be able to receive a stem cell transplant if this treatment helps.
Houston, TexasAges Up to 75 years - NCT06317649RecruitingPhase 2
Venetoclax with hypomethylating agents for older or unfit adults with FLT3-mutated AML
This trial tests a combination of medicines (venetoclax and a hypomethylating agent) for people with acute myeloid leukemia (AML) who have a FLT3 mutation. It may be an option for older adults or those who cannot tolerate intensive chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT06297551Recruiting
Study of leukemia stem cell markers in AML
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
Stony Brook, New YorkAges 18 years+ - NCT05924750RecruitingPhase 1
Testing a CD33-targeted drug for difficult AML
This Phase 1 trial tests BL-M11D1, a drug designed to target CD33 found on certain AML cells, in adults whose AML has come back or is hard to treat. If you qualify, you may be offered early access to a potential new option while researchers closely monitor safety and side effects.
Hefei, AnhuiAges 18–75 - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT06285890RecruitingPhase 1
HC-7366 study for relapsed or refractory AML
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
Houston, TexasAges 18 years+ - NCT06279572Recruiting
Immune study of azacitidine and venetoclax in first AML treatment
This study looks at the immune system of adults with newly diagnosed AML who receive their first treatment of azacitidine and venetoclax. Researchers want to understand how this chemotherapy affects your immune cells.
Scottsdale, ArizonaAges 18 years+ - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Birmingham, AlabamaAges 1–18
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia, myeloid, acute?
- Yes. Clin2 currently lists 595 recruiting leukemia, myeloid, acute studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, myeloid, acute trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, myeloid, acute trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.